Moderna Inc. said Monday its experimental flu shot showed positive results in a late-stage trial. In a Phase 3 study, the ...

Moderna’s mRNA flu shot outperforms existing vaccines in Phase 3 trial, showing over 26% greater efficacy—paving the way for ...

Moderna Inc. said its experimental flu shot met its goal in a late-stage trial, clearing the path for its broader strategy of ...

Influenza hemagglutinin subunit vaccines are more effective and offer better cross protection against various influenza virus ...

Moderna’s latest flu vaccine, based on similar mRNA technology integrated in its COVID-19 shot, displayed optimistic outcomes ...

Moderna said its experimental influenza vaccine showed superior efficacy compared with a licensed standard-dose seasonal flu ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

The virus has not yet evolved to spread efficiently between people. Excellent vaccine technology exists, but the government ...

Questions are answered by experts at the Oregon Health Authority, other state agencies or community partners. Questions and ...

A new slate of vaccine advisers to the US Centers for Disease Control and Prevention voted Thursday to recommend that ...

At first, the monovalent influenza A (H5N8) vaccine will be tested in two doses, 21 days apart, in adults aged 18–59.